alzheimer disease News
-
Lilly`s donanemab slowed Alzheimer`s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found donanemab met its primary endpoint and ...
-
Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease
Optina Diagnostics announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its retinal imaging platform (CAPRS1/MHRC2). Optina Diagnostics’ platform uses Artificial Intelligence (AI) to analyze the data rich hyperspectral retinal images captured with the MHRC during a simple eye scan. Optina Diagnostics’ platform is intended for ...
-
A night at Sardi`s announces 2011 Honoree
The 19th Annual "A Night at Sardi's," a star-studded benefit for the Alzheimer's Association on Wednesday, March 16, 2011 at the Beverly Hilton, will honor The Walt Disney Company's President and CEO Robert A. Iger for his contributions in the fight against Alzheimer's disease. Mr. Iger will receive the Abe Burrows Entertainment Award, which is presented to an individual who has shown an ...
-
DiamiR Announces Oral Presentation at 21st International Conference on Alzheimer`s Drug Discovery
DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Dr. Kira Sheinerman, Chief Executive Officer, will be presenting and participating in a panel discussion at The 21st International Conference on Alzheimer's Drug Discovery hosted by the Alzheimer's Drug Discovery Foundation (ADDF) and held virtually October 5-6, ...
By DiamiR
-
Metlife foundation announces major awards to scientists for research in alzheimer`s disease
The 25th anniversary presentation of the MetLife Foundation Awards for Medical Research in Alzheimer's Disease (AD) was held today honoring two noted researchers, Randy L. Buckner, Ph.D., professor of Psychology and of Neuroscience at Harvard University and Howard Hughes Medical Institute Investigator, and Marcus E. Raichle, M.D., professor of radiology and neurology at Washington University ...
-
Alfa Chemistry Launches Donepezil for Alzheimer's Disease Research
Alfa Chemistry, a long-term partner for many pharmaceutical companies, universities, and research institutions, recently announced to offer donepezil, a synthetic active pharmaceutical ingredient (API) that can be used in pharmaceutical preparation for the treatment of Alzheimer's disease. API refers to the biologically active component of a drug product. In recent decades, the great importance ...
-
Patent Issues for Novel Huntington`s and Alzheimer`s Disease Gene Therapy
Vybion announces the issue by the USPTO of Patent No. 9932394 entitled, "Single Chain Intrabodies that Alter Huntingtin Mutant Degradation". Issued claims cover composition of matter as well as both the Huntingtin and Tau protein targets with the potential for treatment of both Huntington's and Alzheimer's diseases. A continuation on the remaining methods claims has been filed. This patent ...
By Vybion
-
Oxford Brain Diagnostics awarded FDA Breakthrough Device Designation for technology to predict Alzheimer’s Disease
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
-
Putting Alzheimer’s on early notice
The International Conference on Alzheimer"s disease in Hawaii heard that scientists from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) have identified advances in imaging and blood screening that will contribute to the earlier detection of Alzheimer’s. About 250,000 Australians currently have Alzheimer’s disease, but numbers are anticipated to rise ...
-
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques ...
By MorphoSys AG
-
NIH investigators discover new mechanism that may be important for learning and memory
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
-
NIH investigators discover new mechanism that may be important for learning and memory
New findings in mice suggest that the timing when the neurotransmitter acetylcholine is released in the brain's hippocampus may play a key role in regulating the strength of nerve cell connections, called synapses. Understanding the complex nature of neuronal signaling at synapses could lead to better understanding of learning and memory, and novel treatments for relevant disorders, such as ...
-
Alzheimer’s protein puts top brains to the test
Alzheimer’s disease is one of the fastest growing diseases in Australia and the most common form of dementia. The number of people with dementia is expected to rise from 300,000 to 1.13 million by 2050. Alzheimer’s disease is associated with the development of a toxic protein in the brain known as amyloid beta. The amyloid beta protein rapidly self-assembles in the brain and builds ...
-
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose ...
By Optos, Inc.
-
DiamiR Receives Award from Alzheimer`s Drug Discovery Foundation to Accelerate Development of microRNA Biomarkers for Alzheimer`s Disease
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today a $492,000 award in support of the project entitled "Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration." The award will accelerate the development of DiamiR's targeted diagnostic technology for detection and prediction of Alzheimer's disease ...
By DiamiR
-
PERKINELMER AND PREDICTIVE DIAGNOSTICS ANNOUNCE DISCOVERY OF BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE
Results of Joint Study Presented at the American Association for Clinical Chemistry Conference BOSTON & VACAVILLE, CALIFORNIA , April 19, 2005 – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced ...
-
Exercise may help prevent brain damage caused by Alzheimer’s Disease
Regular exercise could help prevent brain damage associated with neurodegenerative diseases like Alzheimer’s, according to research published this month in Elsevier’s journal Brain, Behavior, and Immunity. “Exercise allows the brain to rapidly produce chemicals that prevent damaging inflammation”, said Professor Jean Harry, who led the study at the National Institute of ...
-
Research from Beacon Biosignals Presented at Alzheimer`s Association International Conference
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31–Aug. 4, 2022, in San Diego. Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard ...
-
Untargeted Lipidomics Now Available with Creative Proteomics’s New Cutting-Edge Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology companies, and pharmaceutical companies. The company has recently announced the fully-developed untargeted lipidomics service, which can analyze hundreds of different lipids simultaneously, and is widely used ...
-
Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego. Presentation details ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you